Manuel Carrondo – VJRegenMed

Moving forward in the CGT field using lessons from the pandemic

Simon Ng — Mon, 08 Nov 2021 18:22:08 +0000

Manuel Carrondo, PhD, Instituto de Biologia Experimental e Tecnológica (iBET), Oeiras, Portugal, explains how lessons from the COVID-19 pandemic could positively impact the cell and gene therapy (CGT) space. Importantly, he expects the evidence and understanding obtained from the large-scale use of mRNA- and adenoviral-based vaccines and adenoviruses during the pandemic, which had previously been tested in only a small number of people, will undoubtedly lead to further research and development of these types of therapies. Furthermore, the increased collaboration between companies, researchers and regulators that took place during this period could accelerate CGT product development in the future. This interview took place at the Advanced Therapies Congress & Expo 2021.

The current landscape of viral vector-based gene therapy

admin_vjr_user — Wed, 20 Oct 2021 18:03:49 +0000

Manuel Carrondo, PhD, Instituto de Biologia Experimental e Tecnológica (iBET), Oeiras, Portugal, provides an overview of the current landscape of viral vector-based gene therapy, several of which have already received regulatory approval for the treatment of a number of different diseases. Dr Carrondo draws comparisons with the field of antibody-based cancer therapy and expects the interest in this field of research to continue to grow in a similar manner, particularly for the treatment of rare diseases. This interview took place at the Advanced Therapies Congress & Expo 2021.

The importance of analytical tools in cell and gene therapy manufacturing

admin_vjr_user — Wed, 13 Oct 2021 17:11:07 +0000

Manuel Carrondo, PhD, Instituto de Biologia Experimental e Tecnológica (iBET), Oeiras, Portugal, explains the importance of developing analytical tools to improve the characterization and quality control of viral vector-based gene therapies and cell therapies being manufactured, in order to not only meet regulatory requirements but also allow the improved understanding and optimization of manufacturing protocols. Analytical tools being developed utilize a range of technologies, including machine learning and artificial intelligence (AI), in order to assist in the interpretation of large datasets obtained. This interview took place at the Advanced Therapies Congress & Expo 2021.